Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.

Moss AC, Brinks V, Carpenter JF.

Aliment Pharmacol Ther. 2013 Nov;38(10):1188-97. doi: 10.1111/apt.12507. Epub 2013 Oct 3. Review.

2.

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.

PMID:
25066837
3.

Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.

Cozzani E, Burlando M, Parodi A.

G Ital Dermatol Venereol. 2013 Apr;148(2):171-4.

PMID:
23588142
4.

Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

Frederiksen MT, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K, Steenholdt C.

Inflamm Bowel Dis. 2014 Oct;20(10):1714-21. doi: 10.1097/MIB.0000000000000138.

PMID:
25069030
5.

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.

Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP.

Aliment Pharmacol Ther. 2012 May;35(9):971-86. doi: 10.1111/j.1365-2036.2012.05057.x. Epub 2012 Mar 22. Review.

6.

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6. Review.

PMID:
23223420
7.

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OØ, Brynskov J.

Scand J Gastroenterol. 2009;44(7):774-81. doi: 10.1080/00365520802699278. Review.

PMID:
19140087
8.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L.

Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Review.

PMID:
20485259
9.

Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease.

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.

Inflamm Bowel Dis. 2011 Jan;17(1):91-8. doi: 10.1002/ibd.21362.

PMID:
20564536
10.

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF.

Gastroenterology. 2011 Dec;141(6):2026-38. doi: 10.1053/j.gastro.2011.08.032. Epub 2011 Aug 27.

PMID:
21875498
11.

Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.

Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ; Dutch Delta IBD Group.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):318-21. doi: 10.1016/j.cgh.2012.10.024. Epub 2012 Oct 25.

PMID:
23103819
12.

Maximizing the effect of biologics in inflammatory bowel disease.

Souto Rodriguez R, Swoger JM, Barreiro-De Acosta M, Regueiro M.

Minerva Gastroenterol Dietol. 2012 Jun;58(2):101-22. Review.

PMID:
22643594
13.

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.

Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30.

14.

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR.

Dig Dis Sci. 2013 Apr;58(4):1149-56. doi: 10.1007/s10620-012-2457-0. Epub 2012 Nov 20. Review.

PMID:
23179145
15.

Drug monitoring of biologics in inflammatory bowel disease.

Eser A, Primas C, Reinisch W.

Curr Opin Gastroenterol. 2013 Jul;29(4):391-6. doi: 10.1097/MOG.0b013e328361f7f6. Review.

PMID:
23703367
16.

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M.

Inflamm Bowel Dis. 2012 Jul;18(7):1199-206. doi: 10.1002/ibd.21839. Epub 2011 Aug 29.

PMID:
22127789
17.

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.

Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.

J Gastroenterol. 2014 Jan;49(1):100-9. doi: 10.1007/s00535-013-0803-4. Epub 2013 Apr 11.

PMID:
23575576
18.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, Sampat S, Mendizabal M, Lin MV, Lichtenstein GR.

Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. doi: 10.1016/j.cgh.2010.09.016. Epub 2010 Oct 1. Review.

PMID:
20888436
19.

Optimizing anti-TNF treatments in inflammatory bowel disease.

Ben-Horin S, Kopylov U, Chowers Y.

Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19. Review.

PMID:
23792214
20.

Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.

El Mourabet M, El-Hachem S, Harrison JR, Binion DG.

Curr Drug Targets. 2010 Feb;11(2):234-41. Review.

PMID:
19916950
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk